论文部分内容阅读
目的:了解我院2011~2013年抗肿瘤分子靶向药物的应用情况,为临床合理应用提供参考。方法:对我院2011~2013年抗肿瘤分子靶向药物应用品种、销售金额排序法、用药频度(DDDs)、限定日费用(DDC)等进行回顾分析。结果:我院抗肿瘤分子靶向药物占全院肿瘤用药的比例逐年增加,2012年、2013年构成比超过60%,其中蛋白激酶抑制药(TKI)占肿瘤靶向药物总金额的41.29%~73.41%,单克隆抗体(Mab)构成比19.40%~30.88%,其他药物构成比7.19%~27.83%。利妥昔单抗、西妥昔单抗的消耗金额与用药人次同步性不好,患者承担费用较高。结论:我院抗肿瘤分子靶向药物呈逐年增加趋势,其中尤以口服靶向药物应用更为广泛。
Objective: To understand the application of antitumor molecular targeted drugs in our hospital from 2011 to 2013, and to provide a reference for clinical rational application. Methods: A retrospective analysis was conducted on the application of antitumor molecular targeted drugs, sales amount ranking method, medication frequency (DDDs) and DDC for 2011-2013 in our hospital. Results: The proportion of antitumor molecular targeted drugs in our hospital increased year by year, accounting for more than 60% in 2012 and 2013, of which protein kinase inhibitor (TKI) accounted for 41.29% of the total amount of targeted drugs. 73.41%, the Mab composition ratio was 19.40% -30.88%, the other drug composition ratio was 7.19% -27.83%. The amount of rituximab, cetuximab consumption and drug administration time synchronization is not good, patients bear higher costs. Conclusion: The antitumor molecular targeted drugs in our hospital showed an increasing trend year by year, especially in the oral administration of more targeted drugs.